SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CORT

Corcept Therapeutics Inc (NASDAQ:CORT)

US · Delayed Price · Currency is USD
Also listed: 0I3Q.LHealthcare · Medical - Pharmaceuticals
$63.62-$1.36 (-2.09%)
 
Market cap
$6.96B
Insider Score
Health Score
Analyst consensus
Listed since
Apr 14, 2004
Market Cap$6.96B-18.1%
Revenue (ttm)$963.65M+30.0%
Net Income$162.00M+53.2%
EPS$1.27+44.3%
Shares Out109.44M
PE Ratio42.41
Forward PE13.23
Dividendn/a
Ex-Dividend Daten/a
Volume1,091,156
Open$64.07
Previous Close$64.98
Day's Range$62.88 - $65.13
52-Week Range$28.66 - $126.38
Beta0.45
AnalystsBuy
Price Target$132.80(+108.74%)
Earnings DateFeb 23, 2027

About CORT

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Address
101 Redwood Shores Parkway, Redwood City, CA, 94065, US
Market Cap
6.96 billion
Employees
730
Industrial Classification
Medical - Pharmaceuticals

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$8.58M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $143.50 (+125.6%)

2 firms rating CORT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From CORT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.09%
5 Days
-12.02%
1 Month
-40.82%
6 Months
+5.65%
1 Year
-18.13%

$CORT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CORT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CORT's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CORT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CORT Revenue by Segment

$340.47MTotal
Hypercortisolism Products$249.07M73.15%
Lifyorli$91.41M26.85%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CORT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CORT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CORT

IJHiShares Core S&P Mid-Cap ETF$218.06M
VTIVanguard Morningstar Total Stock Market ETF$197.96M
VBVanguard Morningstar Small-Cap ETF$176.94M
VBKVanguard Morningstar Small-Cap Growth ETF$98.94M
VXFVanguard Extended Market ETF$87.51M
FBTFirst Trust NYSE Arca Biotechnology Index Fund$51.87M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CORT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
17.01
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
62

News check: Positive clinical data on relacorilant efficacy balanced against valuation concerns; concrete case report supports pipeline but stock assessment suggests limited upside.

Recent Insider Activity

Buys
0
Sells
19
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-37.0 since Aug 21
0255075100Aug 21 — Insider Score 37.0Aug 22 — Insider Score 37.0Aug 23 — Insider Score 37.0Aug 24 — Insider Score 37.0Aug 25 — Insider Score 37.0Aug 26 — Insider Score 37.0Aug 27 — Insider Score 37.0Aug 28 — Insider Score 37.0Aug 29 — Insider Score 37.0Aug 30 — Insider Score 37.0Aug 31 — Insider Score 37.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 28.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

LFSCF/M Emerald Life Sciences Innovation ETF3.99%
SPITF/m Emerald Special Situations ETF2.15%
SURISimplify Propel Opportunities ETF1.99%
FBTFirst Trust NYSE Arca Biotechnology Index Fund1.96%
PJPInvesco Pharmaceuticals ETF1.82%
FBT.TOFirst Trust NYSE Arca Biotechnology ETF1.81%
MCOWPacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF1.50%
IHEiShares U.S. Pharmaceuticals ETF1.44%
FHH.TOFirst Trust AlphaDEX U.S. Health Care Sector Index ETF1.43%
ASCEAllspring SMID Core ETF1.38%
FXHFirst Trust Health Care AlphaDEX Fund1.33%
FORHFormidable ETF1.30%

Weight is the stock’s share of each fund’s holdings.